Navigation Links
Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
Date:9/7/2012

THE WOODLANDS, Texas, Sept. 7, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, at 8:00 a.m. EST in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until October 11, 2012.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and invo
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... ISN has released its third annual U.S. ... series. With data aggregated from over eight billion U.S. ... online contractor management platform, ISNetworld, this three-part series provides ... The Contractor Performance Benchmarking ... in two industry specific volumes: Oil & Gas, ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... New System to Streamline Process, Drive Value from ... Software Inc., a leading,provider of web-based employee performance ... been selected by Quiznos to provide a system,for ... is a,national chain with over 5000 franchise restaurants, ...
... Alimera Sciences,and pSivida Ltd (Nasdaq: PSDV ... have amended their license and collaboration agreement relating ... for,diabetic macular edema (DME), and other Medidur products. ... of Medidur FA from 50 to 80,percent in ...
... Million Distribution Contract from Anhui ... Huayuan Pharmaceutical Co., ... Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and,supplier ... today announced that the Company has been granted SFDA,approval ...
Cached Biology Technology:Quiznos Selects Halogen for Fresh Approach to Talent Management 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 2Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 3
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... mesothelioma ?a form of cancer associated with asbestos exposure ?have ... two cancer drugs, a large multicenter study finds. , Mesothelioma, ... the lining of the lungs, heart and abdomen, is associated ... , In the study, patients receiving pemetrexed and cisplatin ?along ...
... virus (IBV) causes losses of £23.6M a year to the ... way to vaccinate chicks against the disease ?one that can ... , A pre-hatching prototype vaccine virus which provides immunity to ... Animal Health (IAH) and vaccine company Intervet UK. It can ...
... may be simpler than what scientists had been assuming. A ... Journal of Biological Chemistry, provides new information on the inner ... the way physicians make livers regrow in patients with liver ... human liver is one of the few organs in the ...
Cached Biology News:Chemo combination improves survival in asbestos-related cancer 2Chemo combination improves survival in asbestos-related cancer 3In-shell vaccine for chick disease 2Liver regeneration may be simpler than previously thought 2Liver regeneration may be simpler than previously thought 3
LTBP-2 (7B10)...
... Mouse monoclonal [198C679.2.1] to Presenilin 2 ... inherited form of the disease carry mutations ... the amyloid precursor protein (APP). These disease-linked ... longer form of amyloid-beta (main component of ...
... Inventory Racks for cryogenic vials. ... cardboard or stainless steel boxes ... cryo vials. Vapor phase ... Platform risers to be ...
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: